NCT04055883View on ClinicalTrials.gov

Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD

PHASE2CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Calcific Aortic Valve Disease
Interventions
DRUG

DA-1229

All participants are administered one tablet per day for 96 weeks

Trial Locations (10)

13620

Seoul National University Bundang Hospital, Seongnam-si

35015

Chungnam National University Hospital, Daejeon

41944

Kyeongpook National University Hospital, Daegu

50612

Pusan National University Yangsan Hospital, Yangsan

61469

Chonnam National University Hospital, Gwangju

06273

Gangnam Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance, Seoul

05505

Asan Medical Center, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT04055883 - Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD | Biotech Hunter | Biotech Hunter